Gladius Capital Management LP Boosts Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Gladius Capital Management LP raised its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 65.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 121 shares of the medical research company’s stock after buying an additional 48 shares during the period. Gladius Capital Management LP’s holdings in Bio-Rad Laboratories were worth $39,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in BIO. Raymond James & Associates lifted its position in Bio-Rad Laboratories by 2.3% during the third quarter. Raymond James & Associates now owns 34,732 shares of the medical research company’s stock valued at $12,450,000 after purchasing an additional 767 shares in the last quarter. New York State Teachers Retirement System lifted its position in shares of Bio-Rad Laboratories by 0.5% during the 3rd quarter. New York State Teachers Retirement System now owns 15,952 shares of the medical research company’s stock valued at $5,718,000 after buying an additional 84 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Bio-Rad Laboratories by 1.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,127 shares of the medical research company’s stock valued at $4,705,000 after acquiring an additional 140 shares during the period. IFM Investors Pty Ltd increased its holdings in Bio-Rad Laboratories by 5.2% in the 3rd quarter. IFM Investors Pty Ltd now owns 4,057 shares of the medical research company’s stock worth $1,454,000 after acquiring an additional 200 shares in the last quarter. Finally, Advisor Partners II LLC raised its stake in Bio-Rad Laboratories by 25.1% during the 3rd quarter. Advisor Partners II LLC now owns 1,336 shares of the medical research company’s stock worth $479,000 after acquiring an additional 268 shares during the period. 65.24% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Royal Bank of Canada reduced their price objective on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a research note on Friday, February 16th. UBS Group lowered their price objective on Bio-Rad Laboratories from $420.00 to $385.00 and set a “buy” rating on the stock in a research report on Wednesday. StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. Finally, Citigroup cut Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $400.00 to $365.00 in a report on Wednesday, April 3rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Bio-Rad Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $461.00.

Insider Activity at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 3,000 shares of Bio-Rad Laboratories stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total value of $1,008,000.00. Following the completion of the transaction, the executive vice president now directly owns 6,942 shares of the company’s stock, valued at approximately $2,332,512. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 17.50% of the stock is owned by insiders.

Bio-Rad Laboratories Price Performance

Shares of BIO stock traded up $9.05 during trading hours on Thursday, hitting $277.31. The stock had a trading volume of 200,651 shares, compared to its average volume of 206,637. The stock’s 50-day moving average price is $314.19 and its two-hundred day moving average price is $313.69. Bio-Rad Laboratories, Inc. has a one year low of $261.59 and a one year high of $431.79. The stock has a market capitalization of $7.91 billion, a price-to-earnings ratio of -12.90 and a beta of 0.94. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.83 and a quick ratio of 4.34.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Tuesday, May 7th. The medical research company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.04 by $0.25. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The business had revenue of $610.82 million for the quarter, compared to the consensus estimate of $619.09 million. During the same quarter in the previous year, the company posted $3.34 EPS. The company’s revenue was down 9.8% compared to the same quarter last year. Equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.